Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?

Documenti analoghi

• Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
  di: Zhang, Zhe, et al.
  Pubblicazione: (2019)
• JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
  di: Gao, Sizhi P., et al.
  Pubblicazione: (2016)
• Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
  di: Tabara, Keisuke, et al.
  Pubblicazione: (2012)
• Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
  di: Choi, Yun Jung, et al.
  Pubblicazione: (2013)
• Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
  di: Yu, Helena A., et al.
  Pubblicazione: (2013)